Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Access to Document

@article{d4d2830ce8d64a30a8d88d581f70a126,

title = "Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL",

author = "\{van Gelder\}, M. and O. Tournilhac and \{te Raa\}, D. and H.P.J. Visser",

note = "Funding Information: None declared. The authors have declared no conflicts of interest.",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.annonc.2021.08.1990",

language = "English",

volume = "32",

pages = "1442--1443",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

AU - van Gelder, M.

AU - Tournilhac, O.

AU - te Raa, D.

AU - Visser, H.P.J.

N1 - Funding Information: None declared. The authors have declared no conflicts of interest.

PY - 2021/11/1

Y1 - 2021/11/1

U2 - 10.1016/j.annonc.2021.08.1990

DO - 10.1016/j.annonc.2021.08.1990

M3 - Comment/Letter to the editor

C2 - 34428511

SN - 0923-7534

VL - 32

SP - 1442

EP - 1443

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -